Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Discussion

Moderator(s)

• 

  David H. Ilson, MD, PhD

  Weill Cornell Medical College, Memorial Hospital, Memorial Sloan Kettering Cancer Center

Panelist(s)

• 

  Cathy Eng, MD, FACP, FASCO

  Vanderbilt-Ingram Cancer Center
  MD Anderson Cancer Center
• 

  Namrata (Neena) Vijayvergia, MD, FACP

  Fox Chase Cancer Center